185225-06-3

Basic information

• Product Name: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one
• Synonyms: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one
• CAS NO: 185225-06-3
• Molecular Formula: C22H26O5
• Molecular Weight: 370.44
• Mol File: 185225-06-3.mol

Chemical Properties

• Boiling Point: 546.8°C at 760 mmHg
• Flash Point: 238.3°C
• Appearance: /
• Density: 1.18
• Vapor Pressure: 5.2E-12mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one(185225-06-3)
• EPA Substance Registry System: (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one(185225-06-3)

Safety Data

• Hazardous Substances Data: 185225-06-3(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
(3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one is used as a potential pharmaceutical compound for its complex structure and functional groups. Its unique molecular architecture may offer opportunities for the development of new drugs or therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-(3-oxo-1-octen-1-yl)-2H-cyclopenta[b]furan-2-one serves as a valuable intermediate or building block for the synthesis of more complex molecules. Its versatile structure allows for further functionalization and modification, making it a useful tool for researchers in organic synthesis.

InChI:InChI=1/C22H26O5/c1-2-3-5-10-16(23)11-12-17-18-13-21(24)26-20(18)14-19(17)27-22(25)15-8-6-4-7-9-15/h4,6-9,11-12,17-20H,2-3,5,10,13-14H2,1H3/b12-11+/t17-,18-,19-,20+/m1/s1

Upstream product

• 110-43-0 n-pentyl methyl ketone 
• 39746-01-5 Benzoic acid (3aR,4R,5R,6aS)-4-formyl-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 
• 36969-89-8 dimethyl 2-oxoheptylphosphonate 
• 61728-15-2 2-oxohexylphosphonic acid dimethyl ester 
• 33803-58-6 1-(triphenylphosphoranylidene)-2-heptanone 
• 172821-93-1 C₁₅H₁₆O₅ 

Downstream Products

• 38873-82-4 (15R)-PGE2 
• 60203-57-8 prostaglandin J₂ 

Relevant articles and documents

Preparation method of carboprost tromethamine intermediate

The invention provides a preparation method of a carboprost tromethamine intermediate. The method comprises the following steps: A) carrying out an oxidation reaction on benzoyl corey lactone alcohol shown in a formula I under the action of a catalyst and an oxidizing agent to obtain benzoyl corey lactone aldehyde shown in a formula II; B) reacting the benzoyl corey lactone aldehyde as shown in the formula II with dimethyl (2-oxoheptyl) phosphonate under the action of alkali to obtain a 15-ketone crude product as shown in a formula III, and recrystallizing the 15-ketone crude product to obtain a 15-ketone pure product; and C) carrying out methylation reaction on the 15-ketone pure product to obtain the carboprost tromethamine intermediate as shown in a formula IV. According to the invention, the use of reagents with high toxicity and serious environmental pollution is avoided; when the carboprost intermediate 15-ketone is prepared, a mixed solvent is adopted for recrystallization, so that column chromatography is omitted, operation is easy and convenient, reagents are saved, and cost is reduced; and in the methylate preparation process, ultralow temperature is avoided, and the reaction time is shortened, so that the energy consumption is reduced, and the purity and the yield are relatively high.

15-ketone preparation method

The present invention relates to a drug intermediate 15-ketone preparation method in chemical field. The preparation method comprises the following steps: (1) (-)-Corey lactone benzoate, an oxidizing agent and a catalyst are added into a first organic solvent for oxidation to obtain a reaction solution A; (2) after a dilute acid is dropwise added into the reaction solution A obtained in the step (1), the solution is stirred and filtered, the filtrate is extracted directly with the first organic solvent, an organic phase is washed with water, dehydrated with a desiccant and filtered to obtain a (-)-Corey lactone benzoate aldehyde solution; (3) Wittig reagent is added into the (-)-Corey lactone benzoate aldehyde solution obtained in the step (2) for Wittig reaction to obtain a reaction solution B, the reaction solution B is concentrated, a second organic solvent is added, and after cooling and crystallization, a crystallization liquid is obtained; and (4) the crystallization liquid obtained in the step (3) is filtered, the filter cake is washed with a third organic solvent, the filter cake is dissolved by the first organic solvent for impurity removal, and after filteration and concentration, an oil matter is obtained. The drug intermediate 15-ketone preparation method has the advantages of good product quality and the like.

PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS

A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysm

Enantio- and stereospecific syntheses of 15(R)-Me-PGD2, a potent and selective DP2-receptor agonist

(Chemical Equation Presented) The first total synthesis of 15(R)-Me-PGD2 3 is reported. The synthesis is based on the enantioselective and stereospecific syntheses of synthon 17 and its attachment to the five-membered ring by a olefin cross metathesis reaction. This approach permits the introduction of a side chain with a predetermined stereogenic center into the prostanoid ring, resulting in the synthesis of 15R-methyl prostaglandin D2 and allows rapid access to other prostanoids.

Method for preparing prostaglandin derivative

Disclosed is a method for preparing a prostaglandin derivative of formula (A): which comprises reacting an aldehyde represented by formula (1): with a 2-oxoalkyl phosphonate in a reaction solvent under the presence of alkali hydroxide as sole base. By carrying out the reaction using an alkali hydroxide as sole base in the reaction system, the desired prostaglandin derivative can be obtained by simple procedures and with high yield.

Synthesis of 15R-PGD2: A potential DP2 receptor agonist

The first total synthesis of 15R-PGD2 3 was accomplished. The approach used in this report is also an efficient method to produce 15R-PGE 2. 15R-PGD2, a potential DP2 receptor agonist, could be an important novel tool for defining the role of this receptor in inflammatory diseases.

First enantioselective total synthesis of (8S,12R,15S)-prostaglandin J2

Enantioselective synthesis of natural PGJ2 has been accomplished for the first time starting from the commercially available enantiopure aldehyde 7 in 10% overall yield. The key reaction was a novel prostaglandin class interconversion, i.e., an

The Aldol Reaction of Substituted Cyclopentane Carbaldehydes with 2-Heptanone. A Novel Approach to the Construction of the Alkyl Side Chain of Prostaglandins

The aldol reaction of suitably substituted cyclopentane carbaldehydes (1a-c, 4) with 2-heptanone affords β-hydroxy ketones (2a-c, 5) in yields up to 60percent.These aldolization products can be dehydrated to known prostaglandin intermediates.Due to the difficulty to convert β,δ-dihydroxy ketones selectively into α,β-unsaturated δ-hydroxy ketones this reaction sequence for the construction of the (E)-3-oxooct-1-enyl side chain of prostaglandins seems to be especially advantageous for the synthesis of 11-deoxy-prostaglandins.